# Growth and metabolic response of surgical newborn fed on a chemically defined diet

G. Peguero MONFORTE, J. Boix- OCHOA, V. Martinez- IBAÑEZ Hospital Infantil Vall d'Hebron, Barcelona, Spain

# Summary

Eight surgical newborn suffering from several pathological conditions were fed by means of a chemically-defined diet by continuous gastroclisis. The diet provided, per kg of body weight per day, 120 kcal, 12.00 gm carbohydrates, 6.85 gm lipids, 2.79 gm proteins and 2.0 mEq sodium. It contained oligopeptides and free amino-acids, dextrinomaltose, medium chain, triglycerides,

sunflower oil, minerals, vitamins and trace elements.

The patients were fed for 30 days with the preparation. It was well tolerated, produced increase in weight and both the clinical and biochemical controls carried out were normal.

Key words: Chemically defined diet, newborn infants

#### Introduction

Elemental, semiclemental, chemically-defined diets, etc., have been used in clinical practice with the aim of preventing or treating the appearance of symptoms of malnutrition. These diets are used for various medical reasons in adults and children. Nevertheless in the neonatal period their use has been limited. The present study examines the effects of a diet designed by us on the growth and metabolic response of a group of surgical newborns fed on it for a period of thirty days.

# Materials and methods

Eight surgical newborn were fed on this diet. They had all previously received a schedule of parenteral nutrition because of several pathological conditions as specified in Table 1, with glucose, amino-acids, fats, electrolytes, vitamins and trace elements according to the previously published design (1). The objective of using this type of nutrition was to facilitate the change from parenteral to normal enteral nutrition and to reduce the time of parenteral nutrition, thereby reducing its risks and possible complications.

TABLE I.

Order No.	Sex	Weight	Age at start	Diagnosis				
1	F	2400 gm	15 days	Necrotizing enterocolitis				
2	M	3600 mg	16 days	Necrotizing enterocolitis				
3	F	2350 gm	8 days	Jejunal atresia				
4	F	2200 gm	20 days	Necroziting enterocolitis				
5	M	1900 gm	12 days	Jejunal atresia				
6	F	3500 gm	13 days	Meconial peritonitis				
7	М	1200 gm	17 days	Necroziting enterocolitis				
8	F	1500 gm	13 days	Jejunal atresia				

### NUTRITIONAL METHOD

Enteral nutrition was started and gradually increased (at the same time as the parenteral supply was reduced), in relation to digestive tolerance, by continuous gastroclisis until reaching 120 kcal per kg body weight per day, at which point the present study was iniciated. After thirty days of feeding the specific controls were discontinued, passing slowly to feed with low lactose content

TABLE II. Composition of the diet

Formula per sachet Carbohydrates			12.00 gm
•	-Polisaccharides	96.3 % 11.56 gm	
	-Maltose	2.5 % 0.30 gm	
	-Glucose	1.2 % 0.59 gm	
			- 05
	Lipids		6.85 gm
	Medium chain triglycerides		4.80 gm
	Sunflower oil		2.05 gm
	Amino-acids and oligopeptides		2.79 gm
Amino-Acids content per 10	ogm of the preparation		
-Glutamic acid	1.886.80 mg	-Treonine	529.06 mg
Aspartic acid	1.102.17 mg	-Arginine	450.36 mg
Proline	1.058.21 mg	-Alanine	439.35 mg
Lysine CIH	1.048.99 mg	-Histidine	271.74 mg
Leucine	1.012.63 mg	-Cystine	271.48 mg
-N-Acetyl-Tyrosine	812.20 mg	-Glycine	267.13 mg
-Isolcucine	652.15 mg	-Methionine	177.25 mg
-Valine	609.34 mg	-Tryptophane	151.13 mg
-Phenylalanine	564.83 mg	-Taurine	39.22 mg
-Serine	539.18 mg		
Electrolyte content per sacl  -Calcium  -Potassium	2.80 mmol 2.51 mmol	- 5.66 mEq - 2.76 mEq	112.00 mg 98.14 mg
	1 00 1		45 // mo
-Sodium	1.99 mmol	- 1.98 mEq	45.77 mg
-Sodium -Chlorides	1.90 mmol	- 1.98 mEq - 1.69 mEq	67.45 mg
-Sodium -Chlorides -Phosphorus	1.90 mmol 1.80 mmol	· 이용하다 전 경기 시작 사람이 있다.	67.45 mg 55.80 mg
-Sodium -Chlorides -Phosphorus -Magnesium	1.90 mmol 1.80 mmol 0.41 mmol	· 이용하다 전 경기 시작 사람이 있다.	67.45 mg 55.80 mg
-Sodium -Chlorides -Phosphorus -Magnesium	1.90 mmol 1.80 mmol 0.41 mmol	· 이용하다 전 경기 시작 사람이 있다.	67.45 mg 55.80 mg
-Sodium -Chlorides -Phosphorus -Magnesium	1.90 mmol 1.80 mmol 0.41 mmol sachet (120 kcal)	· 이용하다 전 경기 시작 사람이 있다.	67.45 mg 55.80 mg
-Sodium -Chlorides -Phosphorus -Magnesium Trace elements content per	1.90 mmol 1.80 mmol 0.41 mmol sachet (120 kcal) 2.00 mg 0.60 mg	· 이용하다 전 경기 시작 사람이 있다.	67.45 mg 55.80 mg
-Sodium -Chlorides -Phosphorus -Magnesium  Trace elements content per -Iron	1.90 mmol 1.80 mmol 0.41 mmol sachet (120 kcal)  2.00 mg 0.60 mg 70.00 mcg	· 이용하다 전 경기 시작 사람이 있다.	67.45 mg 55.80 mg
-Sodium -Chlorides -Phosphorus -Magnesium  Trace elements content per -Iron -Zinc	1.90 mmol 1.80 mmol 0.41 mmol sachet (120 kcal)  2.00 mg 0.60 mg 70.00 mcg 10.00 mcg	· 이용하다 전 경기 시작 사람이 있다.	67.45 mg 55.80 mg
-Sodium -Chlorides -Phosphorus -Magnesium  Trace elements content per -Iron -Zinc -Copper	1.90 mmol 1.80 mmol 0.41 mmol sachet (120 kcal)  2.00 mg 0.60 mg 70.00 mcg	· 이용하다 전 경 시간 시간 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	67.45 mg 55.80 mg
-Sodium -Chlorides -Phosphorus -Magnesium  Trace elements content per -Iron -Zinc -Copper -Iodine	1.90 mmol 1.80 mmol 0.41 mmol sachet (120 kcal)  2.00 mg 0.60 mg 70.00 mcg 10.00 mcg 10.00 mcg	· 이용하다 전 경 시간 시간 (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	67.45 mg
-Sodium -Chlorides -Phosphorus -Magnesium  Trace elements content per -Iron -Zinc -Copper -Iodine -Manganese  Vitami content per sachet -Carnitine	1.90 mmol 1.80 mmol 0.41 mmol  sachet (120 kcal)  2.00 mg 0.60 mg 70.00 mcg 10.00 mcg 10.00 mcg (120 kcal)  20.00 mg	- 1.69 mEq	67.45 mg 55.80 mg 9.97 mg
-Sodium -Chlorides -Phosphorus -Magnesium  Trace elements content per -Iron -Zinc -Copper -Iodine -Manganese  Vitami content per sachet -Carnitine -Vitamin E	1.90 mmol 1.80 mmol 0.41 mmol  sachet (120 kcal)  2.00 mg 0.60 mg 70.00 mcg 10.00 mcg 10.00 mcg 10.00 mcg 10.00 mcg 10.00 mcg 10.00 Tg	- Vitamin D -Pyridoxine HCI	67.45 mg 55.80 mg 9.97 mg
-Sodium -Chlorides -Phosphorus -Magnesium  Trace elements content per -Iron -Zinc -Copper -Iodine -Manganese  Vitami content per sachet -Carnitine -Vitamin E -Ascorbic acid	1.90 mmol 1.80 mmol 0.41 mmol  sachet (120 kcal)  2.00 mg 0.60 mg 70.00 mcg 10.00 mcg	-Vitamin D -Pyridoxine HCI -Thiamine	67.45 mg 55.80 mg 9.97 mg
-Sodium -Chlorides -Phosphorus -Magnesium  Trace elements content per -Iron -Zinc -Copper -Iodine -Manganese  Vitami content per sachet  -Carnitine -Vitamin E -Ascorbic acid -Vitamin A	1.90 mmol 1.80 mmol 0.41 mmol 0.41 mmol  sachet (120 kcal)  2.00 mg 0.60 mg 70.00 mcg 10.00 mcg 10.00 mcg 10.00 mcg 10.00 mcg 10.00 mg 3.77 IU 9.60 mg 450 IU	-Vitamin D -Pyridoxine HCI -Thiamine -Folic acid	72 IU 42 mc 48 mc 4.80 mc
-Sodium -Chlorides -Phosphorus -Magnesium  Trace elements content per -Iron -Zinc -Copper -Iodine -Manganese  Vitami content per sachet  -Carnitine -Vitamin E -Ascorbic acid -Vitamin A -Nicotinamide	1.90 mmol 1.80 mmol 0.41 mmol 0.41 mmol  sachet (120 kcal)  2.00 mg 0.60 mg 70.00 mcg 10.00 mcg 10.00 mcg 10.00 mg 3.77 IU 9.60 mg 450 IU 0.30 mg	-Vitamin D -Pyridoxine HCI -Thiamine -Folic acid -Vitamin K	72 IU 42 mc 48 mc 4.80 mc 4.80 mc 4.80 mc
-Sodium -Chlorides -Phosphorus -Magnesium  Trace elements content per -Iron -Zinc -Copper -Iodine -Manganese  Vitami content per sachet  -Carnitine -Vitamin E -Ascorbic acid -Vitamin A -Nicotinamide -Calcium	1.90 mmol 1.80 mmol 0.41 mmol 0.41 mmol  sachet (120 kcal)  2.00 mg 0.60 mg 70.00 mcg 10.00 mcg 10.00 mcg 10.00 mcg 10.00 mcg 10.00 mg 3.77 IU 9.60 mg 450 IU	-Vitamin D -Pyridoxine HCI -Thiamine -Folic acid -Vitamin K -Biotin	72 IU 42 mc 48 mc 4.80 mc 4.80 mc 1.80 mc
-Sodium -Chlorides -Phosphorus -Magnesium  Trace elements content per -Iron -Zinc -Copper -Iodine -Manganese  Vitami content per sachet  -Carnitine -Vitamin E -Ascorbic acid -Vitamin A -Nicotinamide	1.90 mmol 1.80 mmol 0.41 mmol 0.41 mmol  sachet (120 kcal)  2.00 mg 0.60 mg 70.00 mcg 10.00 mcg 10.00 mcg 10.00 mg 3.77 IU 9.60 mg 450 IU 0.30 mg	-Vitamin D -Pyridoxine HCI -Thiamine -Folic acid -Vitamin K	72 IU 42 mc 48 mc 4.80 mc 4.80 mc 4.80 mc

TABLE III: Side effects

	Cases									
	1	2	3	4	5	6	7	8		
- Abdominal distension	no	no	no	no	no	no	no	nc		
<ul> <li>Vomiting/regurgitation</li> </ul>	no	no	no	no	no	no	no	no		
- Diarrhoea	no	no	no	no	no	no	no	no		
- Dehydration	no	no	no	no	no	no	no	no		
- Edemas	no	no	no	no	no	no	no	no		
- Necrotizing entero-				55.5%		110	110	110		
colitis	no	no	no	no	no	no	no	nc		
- Intestinal bleeding	no	no	no	no	no	no	no	no		

and soon to feeding normal for the age of the child according to general rules of our department.

#### TYPE OF DIET

The formulation took the form of a powder contained in sachets of 23.50 gm and corresponding to 120 kcal. The composition of each sachet of TRIOSORBIN PEDIATRICO is as shown in (Table 2). The method of preparation is very simple: 200 ml distilled water is poured into a vessel along with the contents of one sachet (23.50 gm powder) and the mixture is beaten until the powder is completely dissolved. The contents of one sachet diluted with 200 ml water is equivalent to 120 kcal, 12.00 mg carbohydrate, 6.85 gm fats, 2.79 gm amino-acids and oligopeptides, 112.00 mg calcium, 98.13 mg potassium, 67.45 mg ch-loride, 55.80 mg phosphorus, 45.77 mg sodium and 9.97 mg magnesium. It also contains trace elements, carnitine and vitamins as shown in Table 2. The resultant osmolarity is 155 mOsm/l and the renal contribution of solutes is 16.60 mOsm/200 ml of water and per 120 kcal.

# PARAMETERS STUDIED

The controls to which the patients were submitted during the course of the study were those concerned with the appearance of collateral side affects of the diet, such as abdominal distension, regurgitations, vomiting, diarrhoea, dehydration, edemas, respiratory distress, intestinal bleeding and necrotizing enterocolitis. With regard to clinical paremeters daily weight was studied, using scales with a range of error of 5 gm; cephalic pe-

rimeter, measured weekly and by the same person; and height, also examined weekly and by the same person. The biochemical parameters of the blood were studied on the third, fifteenth and thirtieth days of complete and exclusive feeding with the formulation to determine: urea, total and fractionated proteins, amino-acidemia, triglycerides, cholesterol, phospholipids, free fatty acids, acidbasic balance, electrolytes, minerals and trace elements, glucose, osmolarity. The urine was tested for volume per 24 hours, osmolarity and glucose. The number and characteristics of faeces per 24 hours was checked.

#### RESULTS

The side effects studied and their results, will be found in Table 3. None of the patients showed, in the course of the study, abdominal distension, vomiting and regurgitations, diarrhoea, dehydration, edema, necrotizing enterocolitis, nor hidden or visible blood in the facces. The mean weight gain (Table 4) was 12.5, 15.0, 14.6, 14.3, 16.6, 28.3, 19.0 and 15.0 gm/day for the correlative cases 1 to 8 respectively. The volume of urine ex-

TABLE IV: Weight gain

Cases	Initial	15	3 0	gm/day		
	weight	days	days	3.00		
1	2400	2580	2770	12.5		
2	3600	3780	4050	15.0		
3	2350	2570	2790	14.6		
4	2200	2390	2630	14.3		
5	1900	2200	2400	16.6		
6	3500	3940	4350	28.3		
7	1200	1570	1770	19.0		
8	1500	1740	1970	15.0		

TABLE V: Urinary parameters

Urine	1	2	3	4	5	6	7	8
- Volume cc/kg/h Osmolarity	2.5 112	2.5 97	2.0 90	2.1 85	3.0 93	2.7 101	2.2 122	2.5 100
- Glucose	neg.	neg.	neg.	neg.	neg.	neg.	ncg.	neg

creted as well as its osmolarity (Table 5) were within normal range. No glucosuria whatsoever was noted. The faeces were few in number weighting some 5 gm gren-ish and lumpy.

The blood levels of hemoglobin, total proteins, total lipids, triglycerides, cholesterol, glucose, urea, sodium, chlorides, potassium, calcium, phosphorus, iron, zinc, copper and magnesium and osmolarity were normal. The values of acidbasic balance as well as those of the figures refering to protein fractioning were within normal range.

The determinations of plasma amino-acids which were carried out (Table 6) proved the absence of any dangerously high amino-acid level. The level of taurine an amino-acid absent from the majority of artificial formulations and the mixtures of intravenous aminoacids for parenteral nutrition, showed a progressively increasing concentration in every case, except No.4, although even here it was within normal range. The level of free fatty acids in the plasma (Table 7) showed, in the 3 cases where it was possible to acquire information, levels rich in the essential fatty acids linoleic acid (18:2 w 6) and arachidonic acid (20:4 w 6). Nevertheless, the values for linolenic acid (18:3 w 3), although acceptable, suffered a gradual decrease. The same occured with one of its metabolites, docosahexaenoic acid (22:6 w 3). The triene/tetraene ratio (20:3 w 9): (20:4 w 6) was always less than 0.4. The linoleic acid (18:2 w 6) / linolenic acid (18:3 w 3) ratio showed everincreasing values as the study progressed.

#### Discussion

The results show the effectiveness of a chemically-deefined diet with regard to the supply of nutri-

tive elements in a group of surgical newborn. Elemental, semi-elemental and chemically-defined diets have been used in several clinical states such as catabolism (2), short bowel syndrome (3,4,5), refractor diarrhoea (6,7), several surgical disorders (8) and we have proposed its use with the aim of reducing the length of a schedule of parenteral nutrition and avoiding its risks and complications: at the same time it considerably facilitates the change from parenteral nutrition to normal enteral nutrition (9). The advantages given by chemically defined diets with regard to the group of children with which we are aconcerned can be explained and summed up in the following way.

The use of glucose polymers has increased over the last ten years for the manufacture of nutritional diets, substituting the monosaccharides and/or disaccharides with the aim of reducing the osmolarity of the formulation without changing the caloric supply. Pancreatic alpha-amylase is the main enzyme which participates in the hydrolisvs of starch and possibly in that of glucose polymers. Nevertheless its concentration is nil or extremely low in the first six months of life (10,11,2,13,14). There are several enzymes capeble of compensating for deficient pancreatic amylase activity: these enzymes are: glycoamylase, salival and lacteal amylase. Glycoamylase is found in the brush border of the cells of the small intestine at concentrations, in the earlier stages of life, similar to those found in the adult and is very resistant to lesions provoked especially when compared with enzymes as labile as lactase (15), in the intestinal mucosa.

Lactase activity in viable human foctus between the l6th and 34th weeks of gestation is about 30 % of that observed in a neonate born at term <sup>(16)</sup>. It is well known that in a newborn or suckling

TABLE VII: Fatty acids in plasma

Aminoscid								Cases				Esten and de				
Treaming				1	2	3			6	7	. 8		1	2	3	Cases 4
Thesaine   B   75   90   39   39   40   43   54   40   40   40   41   42   12   12   12   12   12   12	Taurine	Α		50	60	30	41	22	1020	20	30	10:00	Α	0.37	0.10 tr	
Treenine A 103 150 120 95 145 — 186 126 126 A 107 006 N 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				75	90	39	39	40	43	34	40		В	0.14	1.22 tr.	0.01
B				0.3	80	39	30	50	51	39	51		C	1.34	0.23	0.81
Serine   10	Treonine				150	120	95	145		189	126					1200000
Series   A										181		Launc				
Selone A 147 100 98 94 90 - 137 114 Myvince B 0.83 0.60 0.60 0.60 0.60 0.60 0.60 0.60 0.6		C		80	150	160	150	186	180	176	115					0.27
B	Serine	A		147	100	96	94	90		137	114					
Glutamine + A								130				,				
Glatamine + A		C		-	145	100	132	266	260	155	207	16.0		24.62	20.47	20.05
**************************************	Glutamine +	A		730	630	530	520	523	22	227						
Proline	asparragine					680							C	23.37		
Preline B 1 211 198 — 138 139 245 161 531 C - 210 180 230 186 178 186 182 18.0 A 10.4 10.5 10.5 10.5 10.5 10.5 10.5 10.5 10.5		C		623	520	560	500	580	570	560	565	16:1 w 7	Α	5.02	4.25	1 34
B	Proline	A		197			178	120		250	200		В	4.55	2.67	
Gibtanic A 66 71 60 77 80 78 8 - 63 107 8 16 178 186 182 18.0 A 10.43 9.66 12.66 Gibtanic A 66 71 68 - 63 107 8 8 - 63 107 8 8 10.61 0.61 12.66 12.67		В											С	2.22	2.64	2.40
Company   Comp		C		-	210	180						18.0	A	10.43	9.66	12.66
B	Glutamic	Δ		66	71	60	22			68		Stearic acid				10.62
C	Old Millio												C	11.03	9.15	11.29
Marchidenic   A   30   47   45   45   55   55   79   59   50   10-41   16-51   16-52   16-55   16-56		C														
B	Tentanaina			20			923					Oleic				
C 20 30 83 70 77 80 75 77 Elicide B 25.92 27.76 242.5  Leacine A 64 48 74 65 64 - 132 105	Isoleucine													10.41	10.03	10.30
Leacine A 64 48 74 65 64 - 132 105																
Labelline									523	0,50	.6.6	Linoleic				
C 41 60 90 74 80 100 110 103	Leucme											Transport Transport		1900		
Tyrosine A 84 60 57 25 67 — 87 85												18:3 w 6				
B   35   66   116   99   99   90   80   85   18.3 \	2 0					25,733		- 00	100	110	103					
C	Tyrosine		10									18-3 w 3	۸	0.37	0.55	0.74
Phenilalanine A 36 51 40 49 70 - 60 52 20.3 w 9 A 0.20 0.12 0.07																
B 55 49 66 38 51 53 38 45 15 15 15 15 10 10 10 10 10 10 10 10 10 10 10 10 10							0,	00	07	0.3	90		C	0.16	0.30	0.37
Ornithine  A 34 30 49 37 60 66 66 60 68 64 66 60 68 64 66 60 68 64 60 68 64 60 68 64 60 68 64 60 68 64 60 68 64 60 68 64 60 68 64 60 68 64 60 68 64 60 68 64 60 68 64 60 68 64 60 68 64 60 68 68 64 60 68 68 68 60 60 68 68 68 60 60 68 68 68 60 60 68 68 68 60 60 68 68 68 60 60 68 68 68 60 60 68 68 68 60 60 68 68 68 60 60 68 68 68 60 60 68 68 60 60 68 68 60 60 68 60 60 68 60 60 68 60 60 68 60 60 68 60 60 68 60 60 68 60 60 68 60 60 68 60 60 68 60 60 68 60 60 60 60 60 60 60 60 60 60 60 60 60	Phenilalanine											20:3 w 9	Α	0.20	0.12	0.07
Omithine A 34 30 49 37 60 - 90 72 20.3 w 6 A 1.51 1.43 0.93   B - 59 100 80 185 165 69 117 Dickence B 2.40 2.16 1.99 gammar C 1.81 1.83 1.68   Glycine A 447 135 162 192 145 - 190 103 20.4 w 6 A 6.0 4 5.45 5.42   B 208 218 238 145 245 138 140 - Arachidonic B 7.76 6.43 6.66 C 186 193 193 170 183 - 186 185 C 7.40 7.22 7.65   Valine A 118 100 135 132 155 - 204 194 20.5 w 3 A													В	0.52		0.39
B - 59 100 80 185 165 69 177 20 1176 B 2.40 2.16 1.99 C - 45 90 49 95 86 88 87 2 2 2 2 2 2 2 4 4 6 A 6.04 5.45 5.42 C 186 193 193 170 183 - 186 185 Arachidonic B 7.76 6.43 6.66 C 186 193 193 170 183 - 186 185 Arachidonic B 7.76 6.43 6.66 B 101 99 143 180 185 105 143 124 Eicospenta B				10	70	50	00	00	00	08	64		С	0.26 tr.		0.21
C - 45 90 49 95 86 88 87 linoleic  Glycine A 447 135 162 192 145 - 190 103 20.4 w 6 A 6.04 5.45 5.42   B 208 218 238 145 245 138 140 - Arachidonic B 7.76 6.43 6.66   C 186 193 193 170 183 - 186 185	Omithine								_	90	72					
Glycine A 447 135 162 192 145 — 190 103 20.4 w 6 A 6.04 5.45 5.42   B 208 218 238 145 245 138 140 — Arachidonic B 7.76 6.43 6.66   C 186 193 193 170 183 — 186 185 C 7.40 7.22 7.65   Valine A 118 100 135 132 155 — 204 194 20.5 w 3 A — — — — — — — — — — — — — — — — — —																
B 208 218 238 145 245 138 140 — 204 140				-	43	90	49	95	80	88	87		_	1.01	1.03	1.00
Valine A 118 100 135 132 155 - 204 194 20:5 w 3 A	Glycine						192	145	-	190	103	20.4 6		6.04		5 40
Valine A 118 100 135 170 153 - 186 185																
B 101 99 143 180 185 105 143 124 Eicospenta B		C		100	193	193	170	183		186	185			7.40		
B	Valine				100	135	132	155		204	194	20:5 w 3	Α	5.54	22	
Methionine A 17 12 30 15 20 - 17 21 22:4 W 6 A 0.31 0.27 0.22 B 19 16 18 12 16 19 23 13 B 0.39 0.34 0.32 C 28 30 26 20 18 26 30 28 C 0.48 0.33 0.35 C 0.48 0.39 0.35 C 0.48 0.33 0.35 C 0.48 0.39 0.35 C 0.48 0.33 0.35 C 0.48 0.33 0.35 C 0.48 0.35 C										143			В	1 11112	E 12	
B		C		112	145	205	145	150	143	183	163	eonoic	C		= =	12
B 19 16 18 12 16 19 23 13 B 0.39 0.34 0.32 C 28 30 26 20 18 26 30 28 C 0.48 0.33 0.35 C 0.48 0.39 0.39 0.34 0.35 C 0.48 0.33 0.35 C 0.34 0.34 0.34 0.34 0.34 0.34 0.34 0.34	Methionine	A		17	12	30	15	20	22	17	21	22:4 W 6	A	0.31	0.27	0.22
Histidine A 65 36 53 31 53 — 58 63 C 0.48 0.33 0.35 B 30 34 60 63 73 33 47 60 22:5 W 3 A 0.24 0.21 0.14 C 26 50 75 53 63 38 43 40 B 0.52 0.44 0.51 C 0.66 0.42 0.59 C 0.50 C 0.66 0.42 0.59 C 0.50 C 0.66 0.42 0.59 C 0.50 C 0.66 0.42 0.59 C 0.50 C 0.66 0.42 0.59 C 0.66 0.42 0.59 C 0.50 C 0							12	16		23	13		В	0.39	0.34	0.32
Histidine A 65 36 53 31 53 - 58 63  B 30 34 60 63 73 33 47 60 22:5 W 3 A 0.24 0.21 0.14  C 26 50 75 53 63 38 43 40 B 0.52 0.44 0.51  C 0.66 0.42 0.59  Lysine A 126 70 76 95 80 - 123 86 Decosahexa- B 0.89 1.69 1.13  B - 120 136 70 75 102 106 104 enoic C 0.75 0.96 0.81  Tryptophane A 30 - 38 66 acid mg/dl B 228.8 214.3 252.2  B 61 27 24 24 Total fatty A 325.1 348.6 511.3  C 233 24 Total fatty A 325.1 348.6 511.3  C 23 24 Total fatty A 325.1 348.6 511.3  Arginine A 35 34 43 41 38 - 55 47 20.3 w 9 C 0.14 - 0.02  Arginine A 35 34 43 41 38 - 55 47 20.3 w 9 C 0.14 - 0.02  B - 68 46 34 50 46 40 43 20.24 w 6 C 71 61 40 61 48 58 50 54 N 0.4  A = Sample obtained after 3 days of study  B = Sample obtained after 3 days of study  C = Sample obtained after 15 days of study  C = Sample obtained after 3 days of study  C = Sample obtained after 3 days of study  C = Sample obtained after 3 days of study  C = Sample obtained after 3 days of study  C = Sample obtained after 3 days of study  C = Sample obtained after 3 days of study  C = Sample obtained after 3 days of study		С		28	30	26	20	18	26	30	28					
B 30 34 60 63 73 33 47 60 22:5 W 3 A 0.24 0.21 0.14 C 26 50 75 53 63 38 43 40 B 0.52 0.44 0.51 C 0.66 0.42 0.59 C 0.69 C 0.42 0.59 C 0.69 C 0.42 0.59 C 0.69 C 0.44 0.51 C 0.66 0.42 0.59 C 0.69 C 0.42 0.59 C 0.69 C 0.44 0.51 C 0.66 0.42 0.59 C 0.69 C 0.	Histidine	A		65	36	53	31	53	_	58	63		C	0.48	0.33	0.35
C 26 50 75 53 63 38 43 40 B 0.52 0.44 0.51 C 0.66 0.42 0.59  Lysine A 126 70 76 95 80 - 123 86 Decosahexa B 0.89 1.69 1.13 B 0.89 1.69 1.13 C 166 104 enoic C 0.75 0.96 0.81 C 167 126 98 90 120 115 109 108  Tryptophane A 30 - 38 66 T 123 86 Decosahexa B 0.89 1.69 1.13 109 108  Tryptophane A 30 - 38 66 24 24 - 2 104 105 109 108  Arginine A 35 34 43 41 38 - 55 47 203 w 9 C 234.5 205.7 215.3 C 71 61 40 61 48 58 50 54 N 0.4  A = Sample obtained after 3 days of study  B = Sample obtained after 15 days of study  C = Sample obtained after 15 days of study  C = Sample obtained after 30 days of study  C = Sample obtained after 15 days of study  C = Sample obtained after 30 days of study  C = Sample obtained after 30 days of study  C = Sample obtained after 30 days of study  C = Sample obtained after 30 days of study  C = Sample obtained after 30 days of study  C = Sample obtained after 30 days of study					34	60	63					22:5 W 3	Α	0.24	0.21	0.14
Lysine A 126 70 76 95 80 - 123 86 Decosahexa B 0.89 1.69 1.13 B - 120 136 70 75 102 106 104 enoic C 0.75 0.96 0.81 C 167 126 98 90 120 115 109 108  Tryptophane A 30 - 38 66		C		26	50	75	53	63	38	43	40				0.44	0.51
Lysine A 126 70 76 95 80 - 123 86 Decosahexa B 0.89 1.69 1.13 B - 120 136 70 75 102 106 104 enoic C 0.75 0.96 0.81 C 167 126 98 90 120 115 109 108  Tryptophane A 30 - 38 66 Total fatty A 325.1 348.6 511.3 C 23 24 24 U 234.5 205.7 215.3 C 23 Triene/tetraene A 0.13 0.02 0.12  Arginine A 35 34 43 41 38 - 55 47 20.3 w 9 C 0.14 - 0.02 B - 68 46 34 50 46 40 43 20.4 w 6 C 71 61 40 61 48 58 50 54 N 0.4  A = Sample obtained after 3 days of study B = Sample obtained after 15 days of study C = Sample obtained after 30 days of study C = Sample obtained after 30 days of study C = Sample obtained after 15 days of study C = Sample obtained after 30 days of study C = Sample obtained after 30 days of study C = Sample obtained after 30 days of study C = Sample obtained after 30 days of study C = Sample obtained after 30 days of study C = Sample obtained after 30 days of study													C	0.66	0.42	0.59
B - 120 136 70 75 102 106 104 enoic C 0.75 0.96 0.81  Tryptophane A 30 - 38 66	Lysine	A		126	70	76	05	80		122	96					
C 167 126 98 90 120 115 109 108  Tryptophane A 30 - 38 66	•	В														
Tryptophane A 30 - 38 66 acid mg/dl B 228.8 214.3 252.2  B 61 27 24 24 Triene/tetraene A 0.13 0.02 0.12  Arginine A 35 34 43 41 38 - 55 47 20.3 w 9 C 0.14 - 0.02  B - 68 46 34 50 46 40 43 20.3 w 9 C 0.14 - 0.02  C 71 61 40 61 48 58 50 54 N 0.4  A = Sample obtained after 3 days of study  C = Sample obtained after 15 days of study  C = Sample obtained after 30 days of study  C = Sample obtained after 30 days of study  18:2 w 6		C		167	126	98	90	120								0.01
B 61 27 24 24 Triene/tetraene A 0.13 0.02 0.12  Arginine A 35 34 43 41 38 - 55 47 ratio. B 0.21 0.05 0.05  B - 68 46 34 50 46 40 43 20.3 w 9 C 0.14 - 0.02  C 71 61 40 61 48 58 50 54 N 0.4  A = Sample obtained after 3 days of study  B = Sample obtained after 15 days of study  C = Sample obtained after 30 days of study  C = Sample obtained after 30 days of study  18:2 w 6	Tryptophane	A		30		38	66									
C 23	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	В						-								
Arginine A 35 34 43 41 38 - 55 47 ratio. B 0.21 0.05 0.05 B - 68 46 34 50 46 40 43 20.3 w 9 C 0.14 - 0.02 C 71 61 40 61 48 58 50 54 N 0.4  A = Sample obtained after 3 days of study B = Sample obtained after 15 days of study C = Sample obtained after 30 days of study C = Sample obtained after 30 days of study  18:2 w 6		C		23	-	**	/ <del></del>	-				Teiono/toteone		0.12	0.00	
B - 68 46 34 50 46 40 43 20.3 w 9 C 0.14 - 0.02 C 71 61 40 61 48 58 50 54 N 0.4  A = Sample obtained after 3 days of study B = Sample obtained after 15 days of study C = Sample obtained after 30 days of study  B = Sample obtained after 30 days of study  C = Sample obtained after 30 days of study  18.2 w 6	Arginine	Δ		35	34	42	41	20								
C 71 61 40 61 48 58 50 54 N 0.4  Linoleic/ A 76.54 50.4 32.7  Linoleic/ B 172.8 124.7 91.3  B = Sample obtained after 15 days of study  C = Sample obtained after 30 days of study  18:2 w 6													C	0.14		
Linoleic/ A 76.54 50.4 32.7  A = Sample obtained after 3 days of study linolenic/ B 172.8 124.7 91.3  B = Sample obtained after 15 days of study ratio C 194.5 117.0 85.6  C = Sample obtained after 30 days of study 18:2 w 6		C		71												
A = Sample obtained after 3 days of study B = Sample obtained after 15 days of study ratio C = Sample obtained after 30 days of study 18:2 w 6										222	2000		, (ca.); II		222700	
B = Sample obtained after 15 days of study  ratio  C = Sample obtained after 30 days of study  18:2 w 6	A = Sample obt	ained a	fter 3	days of stu	dv											
C = Sample obtained after 30 days of study 18:2 w 6	B = Sample obta	ained a	fter 15	days of st	udy							ratio	ć			
18:3 w 3	C = Sample obta	ained a	fter 30	days of st	udy											mention.
												10:3 W 3				

infant, in the event of any kind of intestinal or even extra-intestinal damage, such as a surgical intervention, lactase is the first enzyme to go and the last to return.

Under normal circumstances the proteins in the diet should be attacked by gastric and duodenopancreatic enzymes so that the jejunal enterocyte receives the products of protein digestion in the form of oligopeptides (3-6 remains of aminoacids). These are the most numerous, although small quantities or di- or tripeptides and free amino-acids may also be found. The aminooligopeptidases but very little against dipeptides, act on the oligopeptides producing di- and tripeptides. The intracellular peptidases with great activity against dipeptides and less against tripeptides and little or none against oligopeptides, are those charges with the last function necessary for the absorption of amino-acids. Hence it seems evident that, under normal conditions, the proteins of the diet must arrive at the jejunal enterocyte in the form of free amino-acids, dipeptides or oligopeptides, so that after they have been worked on by the intracellular enzyme systems or those of the brush border they are in a readily absorbable form.

The nitrogen supply is mainly provided in the form of di- and tripeptides and free aminoacids, it will be possible to achieve greater acceptance and usability than if we provide intact proteins or large peptides <sup>(17)</sup>.

The allergenic power of lacteal proteins is, from greater to lesser strength, beta-lactoglobulins, alpha-lacto-albumin, casein and serum albumin. Soya proteins also have allergenic capacity (17,18). The excessive uptake of macromolecules may be secondary to damage to the intestinal mucosa (20).

We have attempted to make the formula as similar as possible to the concentrations found in mother's milk. THe most remarkable point in this respect is the richness in taurine, lacking from the majority of commercial formulations, which is essential for the newborn infant (21,22). Human milk contains a considerable quantity of

taurine, while cow's milk, the basis for the preparation of artificial formulations, contains minimal quantities (21,23). The possible relevance of taurine has been associated with neurotransmission, retinal, cardiac and muscular funtion (24,25,26,27) and as a growth modulator, since it is found in particularly high concentrations in excitable tissues or those in the process of development, especially during periods of rapid cellular poliferation (28,29).

The plasma amino-acid levels observed in our patients showed the absence of dangerously high levels of any amino-acid. The taurine levels gave values within normal range in every case and the figures underwent a progressive increase except number 4. This fact seems to indicate that the taurine in the diet is completely utilized and taken advantage of by the body.

The supply of lipids was by means of medium chain tirglycerides and essential fatty acids (17).

MCTs limit the necessities for biliary salts and pancreatic lipase, with regard to the digestion and absorption of fats, absent or very scarce in premature infants, and are absorbed directly by portal route. Although their caloric strength is less in long chain triglycerides, the MCTs can increase the intestinal absorption of calcium (30) and improve nitrogen retention (31). The linoleic acid content of sunflower oil is 68 % the total of fatty acids.

In only three of the eight cases studied was it possible to obtain information on the total fatty acid values. The patients showed levels rich in linoleic acid (18:2 w 6) and aracnidonic acid (20:4 w 6), the two fatty acids where no doubt exists as to their essential character, since only the administration of linoleic acid or its long chain metabolites, especially arachidonic acid, are capable of preventing or healing the appearance of essential fatty acid deficiency in patients undergoing parenteral nutrition without lipids (32). The trienc/ tetraene ratio (20:3 w 9/20:4 w 6) in all our patients demonstrated the absence of essential fatty acid deficiency (index less than 0.4) (33,34). Recently differences of opinion have emerged with regard to the possible essentialness of alphalinolenic acid, since one of its metabolites, eicosapentaenoic acid (20:5 w 3) may be a precursor of series 3 of prostaglandins (35). Furthermore, eicosapentaenoic and docosahexaenoic acids, metabolites of alpha-linolenic acid are found at high concentrations in the phospholipids of the central cerebral cortex and retina (36,37). Consequently some investigators have though that alphalinolenic acid may be an essential fatty acids (alpha-linolenic acid) cannot fulfill all the functions of series w-6 (linoleic acid). The patients included in this study showed acceptable alphalinolenic acid levels, but the plasma levels showed a progressive decrease. One of its metabolites, docosahexaenoic acid showed similar plasma characteristics. In this sense it would be useful to substitute sunflower oil by soya oil, in which the linoleic acid/alpha-linolenic acid ratio is the same as that of breast milk, whose value is 7. The level of alpha-linolenic acid in the milk of the U.S. woman lies between only 0.5 and 1.0 % of total free fatty acids.

Amongst the ingredients of the diet we have included carnitine, a substance indispensible to facilitate the passage of fatty acids with more than 12 carbon atoms to the interior of the mitochondria for subsequent betaoxidation. To cover carnitine needs animals use both endogenously synthesized carnitine and that coming from exogenous sources. Newborn infants fed on diets lacking carnitine show lower serum carnitine levels than those on milk. The reduction of carnitine supply in the neonatal period may cause a reduction in its tissue and blood levels as well as a reduction of urinary excretion.

There are evidence that under such circumstances the utilization of fats is found to be altered (40,41). Unfortunately it was not possible to evaluate carnitinemias in our patients.

The end osmolarity of the mixture as well as the renal load of solutes of the formulation used were found to be within acceptable range <sup>(42,43)</sup> since to provide 120 kcal in 200 ml water the osmolarity is 155 mOsm/l and renal load of solutes are 16.60 mOsm <sup>(43)</sup>. This low osmolarity may allow, under special circumstances, the increase of

caloric density per volumetric unit.

In summary, we have evaluated a chemicallydefined diet administered to a group of newborn infants affected by several pathological conditions. The diet was shown to be beneficial and covered the objectives for which it was conceived. It produced acceptable weight gain without clinical or biochemical abnormalities.

#### REFERENCES

Peguera,G.: Alimentacion parenteral en pediatria. En: Manual de Alimentacion Parenteral. Ed. Toray, Barcelona, 1978.

2. Andrassy RJ, Page CP, Feltman RN: Continual catether administration of an elemantal diet in infants and children. Surgery 82:205, 1977.

3. Voitk AJ, Echeve V, Brown RA: Use of an elemental diet during the adaptation stage of short gut syndrome. Gastroenterology 65:419, 1973.

4. Weinberger M, Rowe MI: Experience with an elemental diet in neonatal surgery. J Pediart Surg 8:174, 1973.

5. Christie DL, Ament ME: Dilute elemental diet and continous technique for managment of short bowell syndrome. J Pediartr 87:705, 1975.

6. Green HK, McCabe DR, Merenstein GG: Protracted diarrhea and malnutrition in infancy: changes in intestinal morphology and disaccharidase activities during treatment with total intravenous nutrition or oral elemental diets. J Pediatr 87:695, 1975.

7. Sherman JO, Hamly CA, Khachadurian AK: Use an oral elemental diet in infancy with severe intractable diarrhea. J Pediartr 86:518, 1975.

tractable diarrhea. J Pediartr 86:518, 1975. 8. Hirai H, Sanada Y, Nakagorwa T: An enteral elemental diet for infants and children with surgical disorders. JPEN 4:460, 1980,

9. Peguero G: Aplicacion de una nueva dieta elemental en neonatologia. II Reunion Internacional de Nutricion Parenteral y Enteral. International Society of Parenteral and Enteral Nutricion. Sociedad Espanola de Nutricion Borcelona. 1980.

10. Delachaume-Salem E, Sarla H: Evolution en function de l'age de la secretion pancreatique humaine normales. Biol Gastroenterol 2:135, 1970.

ll. Zopp G, Andreotti G, Pajno-Ferrara F: Exocrine pancreas function in premature and full-term neonates. Pediartr Res 6:880, 1972.

12. Track NS, Cretzfeldt C, Bokemon M: Enzimatic functional and strutural development in the exocrine pancreas. Comp Biochem Phisiol 51A:95, 1975.

13. Lebenthal E, Lee PC: Development of functional response in human exocrine pancreas. Pediatrics 66:566, 1980.

14. Lebenthal E, Choi FS, Lee PC: The development of pancreatic funtion in premature infants after milk-based and soybased formulas. Pediart Res 15:240, 1981.

- 15. Lebenthal E, Lee PC: Glucoamylase and disaccharidase activities in normal subject and in patints with mucosal injury of small intestine. J Pediart 97:398,1980.
- 16. Antonowicz I, Lebenthal E: Developmental pattern of small intestinal enterokinase and disaccharidase activities in the human fetus. Gastroenterology 72:1299, 1977.
- 17. Adibi SA: Intestinal phase of protein assimilation in man. Am J Clin Nutr 209:205, 1976.
- 18. East am EJ, Lichanea T, Grad MI: Antigenicity of infant formulas: Role of mature intestinal on protein permeability. J Pediatr 93:56l, 1978.
- 19. Whitington PF, Gibson R: Soy protein intolerance. Four patients with concomitant cow's milk intolerance. Pediatrics 59:730, 1977.
- 20. Gruskay FL, Cooke RE: The gastrointestinal absorption of inaltered protein in normal infants and in infants recovering from diarrhea. Pediatrics 16:763, 1955.
- 21. Gaull GE, Rassin DA, Rahia NCR: Milk protein quantity and quality in low birth weight infants. II Effects on sulphur amino acids in plasma and urine. J Pediatr 90:348, 1977.
- 22. Sturman JA Rassin, DH, Gaull, GE: Taurine in developing rat brain. Pediatr Res 11:28, 1977.
- 23. Rassin, DR, Sturman JA, Gaull, GE: Taurine and other free amino acids in milk of man and other animals. Early Develop 2:1, 1978.
- 24. Jacobsen JG, Smith LH Jr: Biochemistry and phisiology of taurine and taurine derivates. Physiol Rev 48:424, 1968.
- 25. Barbeau A, Huxtable RF: Taurine and neurological disorders. New York. Raven Press 1978.
- 26. Huxtable RF Bresler R: Effects of taurine on a muscle intracellular membrane. Biochem Biophys Acta 323:573, 1973.
- 27. Huxtable RF, Bressler R: Taurine concentrations in congestive hearth failure, Science 184:1187, 1974.
- 28. Sturman JA, Rassin DK, Gaull GE: Minireview: Taurine in development. Life Sci 2l:l, 1971. 29. Gaull GE, Wright Ch.E, Saaes CE: Significance of growth modulators in human milk. Pediatrics (Suppl) 75:142, 1975.

- 30. Andrews BF, Loreh V: Improved fat and Ca absorption in LBW fed a medium-chain triglyceride containing formula. Pediatr Res (abstr) 8:378, 1974.
- 31. Tantubhedyangkul P, Hasim SA: Medium-chain triglyceride feeding in premature infants: Effects on fat and nitrogen absorption. Pediatrics 55:359, 1975.
- 32. Burr GO: Significance of essential fatty acids. Fed Proc Am Soc Exp Biol 1:224, 1942.
- 33. Holman RT: Essential fatty acid deficiency in humans. In: Recheigl eds. Handbook of nutrition and foods. Cleveland, Ohio, CRC Press. 1978, 335.
- 34. Holman RT: Essential fatty acids in human nutrition Adv Exp Med Biol. 83:515, 1977.
- 35. Anonymus: Linolenic acid and essential fatty acid. Nutr Rev 37:296, 1979.
- 36. Svennerholm L: Distribution and fatty acid composition of phosphoglycerides in normal human brain. J Lipid Res 9:570, 1968.
- 37. Anderson RE: Lipids of ocular tissue. IV comparison of the phosphilipids from the retina of six mamnalian species. exp Eye Res 10:339, 1970.
- 38. Galli C, Spagnolo C, Agradi E: Lipids. In. Paoletti, R.et al., eds. Biochemistry, vol:1. New York. Raven Press. 1976 237-244.
- 39. Martinez RM: Comunicacion personal.
- 40. Penn F, Wolf H, Schmidt- Sommerfeld E: Possible carnitine deficiency in parenterally alimented newborn infants. Acta Pediatr Scand 296:113 (suppl), 1982.
- 41. Fritz IB, Marquis NR: The role of acylcarnitine esters and carnitine palmitiyl transferase in the transport of acyl groups across mitochondrial membranes. Proc. Natl Acad Sci USA 54. 54:1226, 1965.
- 42. Espgan. Committee on Nutrition. Guidelines on Infant Nutrition. I Recomendations for the composition of an adapted formula. Acta Pediatr Scand Sull 262.1977.
- 43. American Academy of Pediatrics. Committe on Nutrition. Comentary on Breast-Feeding and Infant Formulas: Nutr Rev 34:248, 1976.
- 44. Ziegler EE, Fomon SJ: Fluid intake, renal solute load and water balance in infancy. J Pediatr 78:561, 1971.